Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-181388 in healthy adults
NCT03325075Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Chikungunya virus vaccine (mRNA-1388) in chikungunya virus infection, sponsored by Moderna Inc. Primary endpoint: Number of Participants With Any Solicited Adverse Events at 7 days. Started Jul 2017; status: completed.
02
Drugs
Chikungunya virus vaccine (mRNA-1388)
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03325075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325075.